UBE2I sirna

UBE2I siRNA (Mouse)

Cat. Num. AAA8238220

• Gene Names: Ube2i; UBC9; Ubce9; Ubce2i; 5830467E05Rik; F830028O17Rik
• Reactivity: Mouse
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: UBE2I; UBE2I siRNA (Mouse); UBC9; UBCE2I; UBCE9; SUMO-conjugating enzyme UBC9; SUMO-protein ligase; Ubiquitin carrier protein 9; mUBC9; Ubiquitin carrier protein I; Ubiquitin-conjugating enzyme E2 I; Ubiquitin-protein ligase I; UBE2I sirna

• Host: Synthetic
• Reactivity: Mouse
• Specificity: UBE2I siRNA (Mouse) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 158

• Applicable Applications for UBE2I sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of mouse UBE2I gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for UBE2I sirna

siRNA to inhibit UBE2I expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 294862305
• NCBI GeneID: 22196
• NCBI Accession #: NP_001171080.1
• NCBI GenBank Nucleotide #: NM_001177609.1
• UniProt Accession #: P63280; P50550; Q15698; Q6RUT3; Q86VB3
• Molecular Weight: 18,007 Da
• NCBI Official Full Name: SUMO-conjugating enzyme UBC9
• NCBI Official Synonym Full Names: ubiquitin-conjugating enzyme E2I
• NCBI Official Symbol: Ube2i
• NCBI Official Synonym Symbols: UBC9; Ubce9; Ubce2i; 5830467E05Rik; F830028O17Rik
• NCBI Protein Information: SUMO-conjugating enzyme UBC9
• UniProt Protein Name: SUMO-conjugating enzyme UBC9
• UniProt Gene Name: Ube2i
• UniProt Synonym Gene Names: Ubc9; Ubce2i; Ubce9; mUBC9
• UniProt Entry Name: UBC9_MOUSE

Uniprot Description

UBC9: Accepts the ubiquitin-like proteins SUMO1, SUMO2, SUMO3 and SUMO4 from the UBLE1A-UBLE1B E1 complex and catalyzes their covalent attachment to other proteins with the help of an E3 ligase such as RANBP2 or CBX4. Can catalyze the formation of poly- SUMO chains. Necessary for sumoylation of FOXL2 and KAT5. Essential for nuclear architecture and chromosome segregation. Interacts with HIPK1, HIPK2, PPM1J, RASD2 and TCF3 Interacts with NR2C1; the interaction promotes its sumoylation. Forms a tight complex with RANGAP1 and RANBP2. Interacts with SIAH1 and PARP. Interacts with various transcription factors such as TFAP2A, TFAP2B, TFAP2C, AR, ETS1 and SOX4. Interacts with RWDD3; the interaction enhances the sumoylation of a number of proteins such as HIF1A and I-kappa-B. Interacts with DNMT1. Interacts with FOXL2. Forms a complex with SENP6 and UBE2I in response to UV irradiation. Interacts with human herpesvirus 6 IE2. Interacts with human adenovirus early E1A protein; this interaction interferes with polysumoylation (Probable). Interacts with DNM1l (via its GTPase and B domains); the interaction promotes sumoylation of DNM1L, mainly in its B domain. Interacts with PML-RARA oncoprotein (via the coiled-colied domain); the interaction is required for sumoylation of the PML- RARA oncoprotein. Interacts with IPO13. Interacts with NFATC2IP; this inhibits formation of poly-SUMO chains. Expressed in heart, skeletal muscle, pancreas, kidney, liver, lung, placenta and brain. Also expressed in testis and thymus. Belongs to the ubiquitin-conjugating enzyme family.

Protein type: EC 6.3.2.-; Nuclear receptor co-regulator; Ubiquitin ligase; Ligase; EC 6.3.2.19; Ubiquitin conjugating system; SUMO conjugating system

Cellular Component: nuclear body; PML body; cytoplasm; dendrite; fibrillar center; synapse; nucleus

Molecular Function: protein C-terminus binding; coenzyme F420-2 alpha-glutamyl ligase activity; nucleotide binding; ubiquitin-protein ligase activity; ribosomal S6-glutamic acid ligase activity; SUMO ligase activity; transcription factor binding; protein binding; enzyme binding; UDP-N-acetylmuramoylalanyl-D-glutamyl-2,6-diaminopimelate-D-alanyl-D-alanine ligase activity; bHLH transcription factor binding; coenzyme F420-0 gamma-glutamyl ligase activity; HLH domain binding; ATP binding; ligase activity

Biological Process: proteasomal ubiquitin-dependent protein catabolic process; mitosis; positive regulation of I-kappaB kinase/NF-kappaB cascade; viral reproduction; multicellular organismal development; positive regulation of steroid hormone receptor signaling pathway; protein modification process; protein ubiquitination; negative regulation of transcription from RNA polymerase II promoter; cell cycle; chromosome segregation; protein sumoylation; cell division; positive regulation of transcription factor activity; regulation of receptor activity; negative regulation of transcription, DNA-dependent